Alectinib
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Lorbrena · LORL
ALK TKI · approved 2018 · 8 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A third-generation ALK/ROS1 inhibitor whose renal relevance is tied to edema and prominent metabolic effects.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Lorlatinib is characterized by prominent metabolic effects - hypercholesterolemia and hypertriglyceridemia occur in the majority of patients (the leading grade 3/4 toxicity in the CROWN trial) - plus peripheral edema. Direct renal toxicity is limited and, like other ALK inhibitors, creatinine elevations are generally mild and reversible. Renal effects are not well quantified specifically for lorlatinib.Source: Shaw et al., N Engl J Med 2020 (CROWN); Bonilla et al., Clin Kidney J 2022
Metabolic effects and edema appear within weeks of starting therapy.
Distilled from: “Metabolic effects and edema appear within weeks of starting therapy.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Class-level: ~10% AKI by creatinine (KDIGO) within 90d across ALK-TKIs (incl. lorlatinib); largely reversible tubular-secretion effect on serum creatinine
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.
Case-level dose-dependent proteinuria and biopsy-proven minimal change disease - distinct from the MATE-1 creatinine artifact.
Tap a signature to trace where it strikes the nephron.
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Third-generation, highly CNS-penetrant macrocyclic ALK/ROS1 inhibitor active against most resistance mutations including the compound G1202R/L1196M. Used in ALK-positive non-small-cell lung cancer, first-line and after prior ALK inhibitors.
Class-level context for the major non-renal toxicities of the ALK TKI class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
6 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Quoted verbatim from this agent's current FDA label (Jun 2026) — not paraphrased or interpreted. Full label on DailyMed .
Renal impairment — from the label
In patients with CL cr 15 to <30 mL/min (estimated by Cockcroft‑Gault), the recommended dosage of LORBRENA is 75 mg orally once daily [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3) ] . No dose adjustment is recommended for patients with CLcr 30 to 89 mL/min (estimated by Cockcroft‑Gault) [see Clinical Pharmacology (12.3) ] .
Kidney rows of the label's dosage tables
From the Lorbrena label (Jun 2026) · DailyMed
No row of this label's dosage table names a kidney term together with a withhold, reduce, resume or discontinue instruction. That covers those four instructions in the tables only: a table can still set a starting dose by creatinine clearance, and the prose can give other kidney instructions. The full label on DailyMed has both.
Everything below is FAERS — adverse events someone chose to report, about 7,455 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Reported with a death outcome
2,070 of 7,455 reports
Reported with hospitalization
1,619 of 7,455 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Lorlatinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Alecensa · ALK TKI
Creatinine rise via reduced tubular secretion.
Zykadia · ALK TKI
GI-driven prerenal AKI.
Krazati · KRAS G12C inhibitor
Creatinine rise; emerging data.
Alunbrig · ALK TKI
Creatinine elevation; usually benign.
Bosulif · BCR-ABL TKI
Reversible eGFR decline.
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.